Donepezil Double Blind Trial for ECT Memory Disfunction

Phase 4

Conditions: Schizoaffective Disorder
Schizophreniform Disorder
Schizophrenia

Brief Summary: This is a double blind randomized investigation of donepezil for patients suffering from schizophrenia, undergoing ECT.

Patients will be randomized to receive either donezepil or plasebo, in order to gauge whether donezepil has a protective effect on memory disfunction, while patients are treated with ECT. Several parameters will be invistigated at baseline: general psychopathological measures, memory function scales, side effects scales. The same measurements will be taken throughout the trial and one month after ending the ECT.

Recruitment & Eligibility

Inclusion Criteria

Schizophrenia, Schizoaffective disorder, schizophreniform disorder patients who meet criteria for diagnoses by DSM-IV criteria and evaluated by the Structured Clinical Interview for DSM-IV (SCID)

Exclusion Criteria

History of serious neurological disorders including neurodegenerative deseases, mental retardation, substance and/or alcohol dependence.
Pregnant women
Patients who recieved ECT within 6 month
Patients whith contraindication to Donepezil treatment.
Patients with Lithium treatment

Arm && Interventions

Group	Intervention	Description
Donepezil	Donepezil	-
placebo	Donepezil	-

Primary Outcome Measures

Name	Time	Method
Data will be analyzed using SPSS for Windows.	after 5 ECT treatments
Results of the memory and neurocognitive measures will be examined	after 8 ECT treatments
using repeated MANOVA with before, within and after ECT treatment.	1 month after the last ECT treatment

Secondary Outcome Measures

Name	Time	Method

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial